GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A ...

Refractory chronic cough (RCC), defined as a persistent cough for more than 8 weeks despite adequate treatment of underlying comorbidities, is increasingly acknowledged as a standalone clinical ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

With only days to go until her crucial Budget, the chancellor is heading to Riyadh in search of economic growth. Sean O’Grady ...

Under the deal, France-based Syndivia will receive an upfront payment, as well as development and commercial milestone ...

GSK PLC closed 2.64% short of its 52-week high of £16.85, which the company reached on October 2nd.

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

--GSK has lately posted lower vaccine sales in China and the U.S., and faces pressure to show that its pipeline includes new blockbuster drugs to counter concerns about that slowdown, AJ Bell ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

Market Size was valued at around US $11.9 billion in 2024, the market is projected to surge past US $30.4 billion by 2033, expanding at a robust CAGR of 11.2% (2025?2033). This extraordinary growth ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...